A face can look tired long before it looks aged. Fine crepiness around the eyes, loss of luminosity, fragile skin on the neck and slow recovery after inflammation are often signs of declining tissue quality rather than a simple lack of volume. This is where polynucleotides for skin rejuvenation have attracted serious interest: not as a replacement for sound dermatological care or established aesthetic treatments, but as a biologically oriented approach to supporting skin repair and resilience.
For clinicians, the appeal lies in treatment planning that places tissue health before correction. For patients, it lies in the prospect of improvement that is gradual, natural-looking and respectful of facial anatomy. Both expectations require careful explanation, appropriate product selection and an honest reading of the available evidence.
What are polynucleotides?
Polynucleotides are purified chains of nucleotides, the molecular components associated with DNA and RNA. In aesthetic medicine, injectable polynucleotide preparations are commonly derived from highly purified fish DNA, processed to remove proteins and other material that could increase immunological risk. Products differ in molecular weight, concentration, purification method and regulatory classification, so they should not be regarded as clinically interchangeable.
They are frequently discussed alongside polydeoxyribonucleotide, or PDRN. The terms overlap in everyday clinical conversation, but they are not always identical. PDRN generally refers to shorter DNA fragments, whereas polynucleotide products may contain longer chains. The practical implication is straightforward: practitioners should understand the specific product being used, its approved indication, instructions for use and supporting clinical data rather than relying on broad category claims.
Unlike dermal fillers, polynucleotides are not intended to create immediate structural volume. Unlike botulinum toxin, they do not reduce muscular movement. Their role is better understood as a regenerative adjunct aimed at improving the biological environment of the skin.
How polynucleotides for skin rejuvenation may work
The proposed mechanisms are multifactorial. Polynucleotides have a strong capacity to bind water, which may support hydration within the extracellular environment. They are also thought to influence fibroblast activity, tissue repair signalling and the response to oxidative stress. In laboratory and preclinical settings, nucleotide-based preparations have been associated with processes relevant to wound healing, including cellular proliferation, collagen organisation and modulation of inflammation.
These mechanisms are plausible, but clinical language must remain disciplined. A laboratory finding does not automatically translate into a predictable aesthetic result in every patient. Skin ageing is influenced by ultraviolet exposure, smoking, hormonal change, metabolic health, inflammation, genetics and previous procedures. An injectable treatment can support a broader programme of care; it cannot neutralise all of these factors.
In practice, patients may report better hydration, elasticity, radiance and skin texture over a course of treatments. The most appropriate expectation is refinement, not transformation. This is especially relevant in areas where heavy filler placement may be undesirable, such as the periocular region, neck, décolletage and fine, sun-damaged facial skin.
Selecting the right patient and indication
Patient selection is a clinical judgement, not a marketing exercise. Polynucleotides may be considered for individuals with early to moderate deterioration in skin quality, photoageing, fine lines, dryness, reduced elasticity or a need for tissue support after inflammatory change. They can also have a role within a staged plan for patients who want regenerative treatment before considering volumisation or energy-based procedures.
They are less likely to meet the needs of a patient seeking immediate lifting, correction of pronounced volume loss or removal of deep static folds. In those circumstances, other interventions may be more appropriate, whether that means volumisation, resurfacing, surgery or a decision not to treat. Clear consultation prevents the common error of using a regenerative injectable to solve a structural problem.
A full assessment should include skin condition, facial proportion, medical history, allergies, autoimmune or inflammatory disease, active skin infection, current medication and previous aesthetic treatment. Pregnancy and breastfeeding are generally exclusions in the absence of adequate safety data. Patients with a known sensitivity to fish-derived materials require particular caution, with decisions guided by the product documentation and individual risk assessment.
Treatment planning: technique matters
A high-quality outcome depends as much on technique and judgement as on the injectable itself. The depth, volume, injection pattern, treatment interval and anatomical area should be selected according to the product guidance and the patient’s skin characteristics. Superficial placement can increase the risk of visible papules, irregularity or prolonged swelling, particularly in thin skin. Over-treatment can create unnecessary inflammation without improving the result.
Most protocols involve an initial course, followed by review and, where justified, maintenance treatment. The exact number and interval vary between products and indications. Rather than presenting a fixed package as suitable for everyone, clinicians should assess the skin response over time and adjust the plan accordingly.
Polynucleotides can be incorporated thoughtfully with other treatments, but combination treatment should be sequenced rather than improvised. For example, a clinician may plan regenerative injectables around laser treatment, microneedling, chemical peels or hyaluronic acid filler, allowing adequate time for tissue response and recovery. Combining multiple procedures in one visit may suit selected patients, but it can also make adverse-event assessment more difficult and increase post-treatment inflammation.
Safety and complications management
The perception that regenerative medicine is inherently low risk is misplaced. Any injectable procedure carries risk, including pain, bruising, oedema, infection, inflammatory reactions, nodules and vascular compromise. The risk profile may differ from that of a cross-linked hyaluronic acid filler, but safe practice still requires detailed anatomical knowledge, aseptic technique, informed consent and a documented plan for complications.
Patients should be advised that transient redness, tenderness, bruising and localised swelling can occur. In delicate areas, such as the lower eyelid, swelling may last longer than expected. Persistent lumps, escalating pain, blanching, mottling, visual symptoms or signs of infection require urgent clinical assessment. A practitioner must never allow the apparently gentle nature of a treatment to lower the threshold for escalation.
Product traceability is equally fundamental. Clinics should source products through legitimate medical supply channels, retain batch details and follow storage requirements. Counterfeit, poorly stored or inappropriately administered injectables undermine patient safety and damage confidence in the specialty.
What does the evidence currently show?
The evidence base for polynucleotides is growing, but it remains uneven. Published studies and clinical reports suggest potential improvements in skin hydration, elasticity, texture and patient satisfaction. However, many studies are small, use differing formulations and protocols, have limited follow-up or combine treatments in ways that make it difficult to isolate effect.
This does not mean that the treatment lacks value. It means that claims should reflect the certainty of the data. Larger, well-designed comparative trials, standardised outcome measures and longer-term safety reporting would strengthen clinical decision-making. Until then, the most responsible position is evidence-informed optimism: use products with credible documentation, assess outcomes critically and avoid promising cellular regeneration as though it were a guaranteed or measurable endpoint for every patient.
Photography can support this process when it is standardised. Consistent lighting, positioning, expression and time intervals are essential. Casual before-and-after images rarely provide a reliable account of subtle changes in skin quality.
A regenerative treatment is not a skincare substitute
Injectable polynucleotides should sit within a wider strategy for healthy skin. Daily broad-spectrum sun protection, appropriate topical therapy, smoking cessation, adequate nutrition, management of inflammatory dermatoses and realistic treatment intervals often determine whether an injectable result is sustained or short-lived. Patients who expect an injection to compensate for chronic ultraviolet exposure or untreated rosacea are unlikely to be satisfied.
For medical professionals, this is an opportunity to lead the conversation away from trend-led intervention and towards long-term tissue stewardship. Professor Patrick Treacy’s approach to regenerative aesthetic medicine places that principle at the centre: innovation should be matched by clinical governance, education and an uncompromising commitment to patient welfare.
The best next step is not to ask whether polynucleotides are fashionable, but whether they address the patient’s specific biological and aesthetic concern. When the indication, technique and expectations are aligned, they can be a considered component of modern skin rejuvenation.